We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD and Camtech Health, recently announced their strategic collaboration to uplift cervical cancer screening for women in Singapore by providing them the first-ever option to self-collect a sample amidst the privacy of their own home.
The partnership is intended to raise the percentage of cervical cancer screening in Singapore, where the present screening rate is less than half of eligible women.
Price Performance
For the past six months, BDX’s shares have lost 12.1% compared with the industry’s decline of 5.5%. The S&P 500 increased 12.0% in the same time frame.
Image Source: Zacks Investment Research
More on the News
Cervical cancer is the 10th most common cancer in Singapore, and for women aged 30 to 39, it is the fourth most common cancer. The main obstacles to screening for women in Singapore are time constraints, embarrassment, anxiety, and inconvenience. Until recently, the country only provided HPV testing in hospital or clinic settings, requiring a speculum examination and a physician collection.
The pressing public health issue of reaching women who miss routine cervical cancer screenings can be addressed with the use of at-home collecting. In addition to giving women more access to HPV testing by allowing them to take a sample in private at a time and location of their choosing, self-collection also gives them the assurance that the reliability of their samples is at par with those taken by a clinician.
The program combines the clinically validated BD Onclarity HPV Assay, which can concurrently detect 14 high-risk HPV strains, with the Camtech Health HPV test for self-collection.
Simple steps are involved in taking the HPV test with the Camtech Health app, and the results are mailed back in postage-paid packaging that comes with the kit. The sample is examined using the BD Viper LT fully automated integrated molecular testing system and the BD Onclarity HPV assay. The results are reviewed by a physician and made available on the app, along with a virtual consultation to address any irregularities.
More on BD Onclarity HPV Assay
In a single analysis, the BD Onclarity HPV Assay detects and identifies 14 high-risk HPV types. It also provides genotyping information from specimens collected for cervical cancer screening purposes using the Cervical Brush Diluent tube, Hologic PreservCyt Solution, and BD SurePath Preservative Fluid.
The BD Onclarity HPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm and primary HPV screening. The assay has also met international criteria for primary HPV screening.
The BD Onclarity HPV Assay received the industry's first CE Mark for HPV screening from at-home self-collected vaginal samples.
Industry Prospects
Per a report by Coherent Market Insights, the global cervical cancer diagnostic tests market size was valued at $7.04 billion in 2023 and is expected to grow at 6.3% from 2023 to 2030.
Increased teenage sexual activity, rising incidence of cervical cancer, and high prevalence of (human papillomavirus) HPV-infected individuals are anticipated to drive the growth of the global market for cervical cancer diagnostic tests.
With the given market potential for diagnosing cervical cancer, BD’s collaboration with Camtech Health is likely to boost its business and generate additional revenues.
Notable Developments
In January 2024, BDX announced a strategic collaboration agreement with Techcyte. The tie-up aims to offer an artificial intelligence (AI)-based algorithm that guides cytologists and pathologists to identify evidence of cervical cancer and pre-cancer using whole-slide imaging efficiently and effectively.
In the same month, the company announced its collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications coupled with robotics-compatible reagent kitsto enable greater standardization and reduce human error when conducting large-scale single-cell multiomics experiments.
In December 2023, BD announced the FDA 510(k) clearance for its novel blood collection device, MiniDraw. This revolutionary device is likely to reshape the landscape of diagnostic testing by offering a less invasive and more convenient method for obtaining lab-quality blood samples.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Cencora, Inc. (COR - Free Report) , Elevance Health, Inc. (ELV - Free Report) and Cardinal Health, Inc. (CAH - Free Report) .
Cencora, carrying a Zacks Rank of 2 (Buy), reported first-quarter fiscal 2024 adjusted EPS of $3.28, beating the Zacks Consensus Estimate by 14.7%. Revenues of $72.25 billion outpaced the consensus mark by 5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cencora has a long-term estimated growth rate of 8.6%. COR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.7%.
Elevance Health reported fourth-quarter 2023 adjusted EPS of $5.62, beating the Zacks Consensus Estimate by 1.3%. Revenues of $42.45 billion outpaced the consensus mark by 1.5%. It currently carries a Zacks Rank #2.
Elevance Health has a long-term estimated growth rate of 12%. ELV’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported second-quarter fiscal 2024 adjusted EPS of $1.82, beating the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion surpassed the Zacks Consensus Estimate by 1.1%. It currently carries a Zacks Rank #2.
Cardinal Health has a long-term estimated growth rate of 15.9%. CAH’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 15.6%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD and Camtech Health, recently announced their strategic collaboration to uplift cervical cancer screening for women in Singapore by providing them the first-ever option to self-collect a sample amidst the privacy of their own home.
The partnership is intended to raise the percentage of cervical cancer screening in Singapore, where the present screening rate is less than half of eligible women.
Price Performance
For the past six months, BDX’s shares have lost 12.1% compared with the industry’s decline of 5.5%. The S&P 500 increased 12.0% in the same time frame.
Image Source: Zacks Investment Research
More on the News
Cervical cancer is the 10th most common cancer in Singapore, and for women aged 30 to 39, it is the fourth most common cancer. The main obstacles to screening for women in Singapore are time constraints, embarrassment, anxiety, and inconvenience. Until recently, the country only provided HPV testing in hospital or clinic settings, requiring a speculum examination and a physician collection.
The pressing public health issue of reaching women who miss routine cervical cancer screenings can be addressed with the use of at-home collecting. In addition to giving women more access to HPV testing by allowing them to take a sample in private at a time and location of their choosing, self-collection also gives them the assurance that the reliability of their samples is at par with those taken by a clinician.
The program combines the clinically validated BD Onclarity HPV Assay, which can concurrently detect 14 high-risk HPV strains, with the Camtech Health HPV test for self-collection.
Simple steps are involved in taking the HPV test with the Camtech Health app, and the results are mailed back in postage-paid packaging that comes with the kit. The sample is examined using the BD Viper LT fully automated integrated molecular testing system and the BD Onclarity HPV assay. The results are reviewed by a physician and made available on the app, along with a virtual consultation to address any irregularities.
More on BD Onclarity HPV Assay
In a single analysis, the BD Onclarity HPV Assay detects and identifies 14 high-risk HPV types. It also provides genotyping information from specimens collected for cervical cancer screening purposes using the Cervical Brush Diluent tube, Hologic PreservCyt Solution, and BD SurePath Preservative Fluid.
The BD Onclarity HPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm and primary HPV screening. The assay has also met international criteria for primary HPV screening.
The BD Onclarity HPV Assay received the industry's first CE Mark for HPV screening from at-home self-collected vaginal samples.
Industry Prospects
Per a report by Coherent Market Insights, the global cervical cancer diagnostic tests market size was valued at $7.04 billion in 2023 and is expected to grow at 6.3% from 2023 to 2030.
Increased teenage sexual activity, rising incidence of cervical cancer, and high prevalence of (human papillomavirus) HPV-infected individuals are anticipated to drive the growth of the global market for cervical cancer diagnostic tests.
With the given market potential for diagnosing cervical cancer, BD’s collaboration with Camtech Health is likely to boost its business and generate additional revenues.
Notable Developments
In January 2024, BDX announced a strategic collaboration agreement with Techcyte. The tie-up aims to offer an artificial intelligence (AI)-based algorithm that guides cytologists and pathologists to identify evidence of cervical cancer and pre-cancer using whole-slide imaging efficiently and effectively.
In the same month, the company announced its collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications coupled with robotics-compatible reagent kitsto enable greater standardization and reduce human error when conducting large-scale single-cell multiomics experiments.
In December 2023, BD announced the FDA 510(k) clearance for its novel blood collection device, MiniDraw. This revolutionary device is likely to reshape the landscape of diagnostic testing by offering a less invasive and more convenient method for obtaining lab-quality blood samples.
Becton, Dickinson and Company Price
Becton, Dickinson and Company price | Becton, Dickinson and Company Quote
Zacks Rank & Stocks to Consider
BDX carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Cencora, Inc. (COR - Free Report) , Elevance Health, Inc. (ELV - Free Report) and Cardinal Health, Inc. (CAH - Free Report) .
Cencora, carrying a Zacks Rank of 2 (Buy), reported first-quarter fiscal 2024 adjusted EPS of $3.28, beating the Zacks Consensus Estimate by 14.7%. Revenues of $72.25 billion outpaced the consensus mark by 5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cencora has a long-term estimated growth rate of 8.6%. COR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.7%.
Elevance Health reported fourth-quarter 2023 adjusted EPS of $5.62, beating the Zacks Consensus Estimate by 1.3%. Revenues of $42.45 billion outpaced the consensus mark by 1.5%. It currently carries a Zacks Rank #2.
Elevance Health has a long-term estimated growth rate of 12%. ELV’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported second-quarter fiscal 2024 adjusted EPS of $1.82, beating the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion surpassed the Zacks Consensus Estimate by 1.1%. It currently carries a Zacks Rank #2.
Cardinal Health has a long-term estimated growth rate of 15.9%. CAH’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 15.6%.